Clinical controlled trial of the advanced gastric patients with ascites by intra-abdominal infusion of DC-CIK or rmhTNF
10.11904/j.issn.1002-3070.2015.01.003
- VernacularTitle:DC -CIK 与 rmhTNF 腹腔灌注治疗晚期胃癌恶性腹水的临床对照研究
- Author:
Yuan DING
;
Yuqiang CHEN
;
Yue LI
;
Yanjun MI
;
Yanhua YE
;
Qiang LI
- Publication Type:Journal Article
- Keywords:
DC-CIK;
TNF-α;
Advanced Gastric cancer;
Ascites
- From:Practical Oncology Journal
2015;(1):12-16
- CountryChina
- Language:Chinese
-
Abstract:
Objective This study is to explore the differences in the curative effect of intra -abdominal infusion between Recombinant mutant human tumor necrosis factor and Dendritic cell -Cytokine induced killer . Methods We selected 48 advanced gastric cancer patients with ascites .Those patients were randomized into two groups:DC-CIK group and rmhTNF group .After one month treatment ,we observed the adverse events both two groups,and evaluated the clinical beneficial responses ,the responsive rate ,the tumor indicators′level,the immune indexes and the time of tumor progression .Results In the DC-CIK group,the RR and the CBR were 83.3%and 66.67%,respectively;while in the rmhTNF group,they were 58.33%and 75%,respectively.The difference between two groups was statistically significant (P<0.05).Only CA724 decreased after treatment in two groups (P=0.015).There were no significant differences of tumor markers between the two groups before and after treatment(P>0.05).The ratios of CD3 +、CD4 +、NK cells distinctly increased after treatment (P<0.05),but the ratio of CD8 +cell was no obvious difference in DC -CIK group(P=0.551);The ratio of NK cells increased obviously after treatment(P=0.027),but the ratios of CD3 +and CD4+were similar as previous in rmhTNF group(P>0.05).One year follow-up of the time to progression(TTP)was 7.1 months in DC-CIK group,and 5.8 months in TNF group,which was statistically significant (P=0.02).Conclusion Both rmhTNF and DC-CIK can improve the efficacy for the patients with malignant ascites caused by gastric cancer .However ,DC-CIK immunotherapy shows better active effect on improvement of specific immune function .
